BTT-1029 是一种靶向血管黏附蛋白-1 (VAP-1) 的人源单克隆抗体,可减轻肝纤维化、炎症灶和脂肪变性,降低 α-SMA 与 Ⅰ 型胶原蛋白的表达并减少白细胞募集,可用于非酒精性脂肪性肝炎和肝纤维化的相关研究。
BTT-1029
产品编号: MS-G60265
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

BTT-1029 是一种靶向血管黏附蛋白-1 (VAP-1) 的人源单克隆抗体,可减轻肝纤维化、炎症灶和脂肪变性,降低 α-SMA 与 Ⅰ 型胶原蛋白的表达并减少白细胞募集,可用于非酒精性脂肪性肝炎和肝纤维化的相关研究。

生物实验数据

生物活性 BTT-1029 is a human monoclonal antibody targeting vascular adhesion protein-1 (VAP-1) that attenuates liver fibrosis, inflammatory foci, and steatosis, reduces the expression of α-SMA and type I collagen, and decreases leukocyte recruitment, making it suitable for research on non-alcoholic steatohepatitis and liver fibrosis.
体内研究
(In Vivo)

BTT-1029 (9 mg/kg;静脉注射;每周 1 次;共 8 周) 可显著减轻雌性 C57BL/6 小鼠中 CCl4 诱导的肝纤维化,且不会改变初始肝损伤。
BTT-1029 (9 mg/kg;静脉注射;每周 1 次;共 6 周) 可减轻雄性 C57BL/6 小鼠因 MCD 饮食诱导的非酒精性脂肪性肝炎的脂肪变性、炎症和纤维化。

Animal Model: C57BL/6 (female, 6-8 weeks old, CCl4-induced hepatic fibrosis)
Dosage: 9 mg/kg
Administration: i.v.; weekly; starting prior to CCl4 treatment and continuing through 8-week treatment and 4-week resolution period
Result: Reduced picosirius red staining and α-SMA staining compared to untreated CCl4-exposed WT mice at 8 weeks.
Showed no significant difference in picosirius red and α-SMA staining between 8-week time point and after 4-week resolution period.
Maintained serum ALT levels comparable to untreated CCl4-exposed WT mice.
Showed a trend toward reduced Col1a1 and Acta2 mRNA expression at 8 weeks, with mRNA levels returning to mineral oil control levels after resolution period.
Animal Model: C57BL/6 (male, 6-8 weeks old, MCD diet-induced nonalcoholic steatohepatitis)
Dosage: 9 mg/kg
Administration: i.v.; weekly; starting 1 week pre-diet and continuing for 6 weeks (prophylactic); i.v.; twice weekly; final 4 weeks of 6-week MCD diet (therapeutic)
Result: Reduced liver inflammatory foci, steatosis (Oil red O staining area decreased), and hepatic fibrosis (lower α-SMA staining area, lower Van Gieson's collagen staining area, reduced Acta2 and Col1a1 mRNA expression) compared to untreated MCD-fed WT mice with prophylactic treatment.
Maintained serum ALT levels comparable to untreated MCD-fed WT mice with prophylactic treatment.
Reduced the proportion of hepatic CD19+ B cells and CD11b+F4/80+ macrophages relative to live CD45+ cells, and reduced Acta2 and Col1a1 mRNA expression compared to untreated MCD-fed WT mice with therapeutic treatment.

化学信息

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础